Hamlet Pharma has signed an Agreement with Liansa Pharma Consulting as partner for Regulatory Services.
Hamlet Pharma has signed an agreement with Liansa Pharma Consulting AB – a company focusing on regulatory strategies and communication with regulatory agencies.
The Liansa Pharma Consulting group has extensive experience from the pharmaceutical industry and primarily support small and medium sized biotech companies. While Hamlet Pharma has an extensive regulatory portfolio in place, the consultants will assist Hamlet Pharma with necessary long-term regulatory strategies, drug development, support for clinical trials and documentation. They will also assist the company in the area of pharmaco-vigilance, including planning and oversight of SAE handling for the upcoming clinical study and in compiling of Development of Safety Update Reports.
”I am pleased that Hamlet Pharma has selected us as their regulatory partner for their clinical development and phase II program. Our extensive experience and knowledge in this area will enable us to give personal, flexible and responsible regulatory support to take HAMLET through the phase II clinical trial process,” says Karin Aschan, CEO at Liansa Pharma Consulting AB.
‘’We see Liansa as ideal partners for Hamlet Pharma and look forward to working with them to further the development of HAMLET through phase II trials in patients suffering from cancer’’ says Catharina Svanborg, chairman of the board and founder of Hamlet Pharma.
For more information, please contact
Catharina Svanborg, Chairman of the board, Hamlet Pharma, +46-709 42 65 49
Catharina.svanborg@med.lu.se
Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57
mats.persson@hamletpharma.com
About Hamlet Pharma
Hamlet Pharma AB owns and develops a new technology to kill cancer cells without harming healthy tissues. The HAMLET technology is focused around the HAMLET family of tumoricidal protein-lipid complexes, formed by naturally occurring molecules from human milk and extended to include recombinant variants of the natural substance. HAMLET has validated therapeutic efficacy in clinical studies and animal models, and in many different cellular models of human cancer. HAMLET will now be developed further for Phase II clinical trials, to verify the positive proof of concept studies. Hamlet Pharma AB shares are listed at AktieTorget. HAMLET is an abbreviation for Human Alpha-lactalbumin Made LEthal to Tumor cells.